\
&
Contact us
\
&
Contact us
Published on | 4 years ago
Programmes SPACE Transport Climate/EnvironmentDo you have fresh ideas on how Earth observation data can contribute to monitoring the effects brought on by the COVID-19 pandemic? If so, ESA and the European Commission have launched a new series of monthly challenges asking for innovative solutions on how satellite data can be used to help better understand the effects of the coronavirus on society, economy and the environment.
The first challenge, launched March 1st 2021, focuses on how the pandemic affects shipping traffic as well as related impacts on air and water quality. The general public are invited to propose, and develop, ways to characterise shipping vessel dynamics and their impacts on atmospheric parameters and ocean water quality information using Earth observation data, such as Copernicus Sentinel data.
More information on the challenges and details on how to participate can be found on this page.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
